Taking NSCLC as an example, in the FLAURA2 study43, the combination of EGFR-TKI and chemotherapy demonstrated a significant PFS benefit compared to the EGFR-TKI monotherapy group. This evidence concerns the gene EGFR and non-small cell lung carcinoma.